|Last Update: 05/24/13 - 4:00 PM EDT|
|YTD Performance: 32.07%|
|Previous Close: $35.29|
|52 Week Range: $17.25 - $58.91|
|Oustanding Shares: 59,554,145|
|Market Cap: 2,101,665,777|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||1||1||1||1|
|Growth Rate (Year over Year)||73.85%||21.74%||28.89%||-1.23%|
Shares of QCOR now seen reaching $38, Jefferies said. Estimates also raised on Strong 4Q with robust 2013 outlook. Buy rating.
Martin Zweig had a colorful style and an insightful approach.
QCOR was upgraded from Neutral to Buy, Mizuho said. $41 price target. Company should exceed consensus expectations in the near term.
Shares of QCOR upgraded to Buy from Hold, Jefferies said. $28 price target. Limited downside with improved visibility.
QCOR was downgraded to Market Perform, Leerink Swann said. Valuation call, following Aetna's Acthar decision.
Disappointing earnings results have sent this name cascading lower.
Shares of QCOR now seen reaching $65, Oppenheimer said. Estimates also lowered on revision of Acthar coverage. Outperform rating.
Shares of QCOR downgraded to Hold from Buy, Jefferies said. $30 price target. Aetna policy change is explicit.
Shares of QCOR now seen reaching $45, according to Bank of America/Merrill Lynch. Estimates also reduced, following AET changes for Acthar. Buy rating.
The worst case is priced in, and any positive news would send this one soaring.